Nov 24, 2025

Lantheus to Present Florbetaben F 18 Data at CTAD 2025

Nov 06, 2025

Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 06, 2025

Lantheus Announces Leadership Transition Plan

Oct 30, 2025

Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Oct 28, 2025

Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease

Oct 23, 2025

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

Sep 24, 2025

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

Sep 02, 2025

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 06, 2025

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update